UCB, Revvity, and CHU Dijon-Bourgogne Join Screen4Care as Project Partners
As of 13.06.2024, Screen4Care is pleased to announce that three esteemed partners have joined our consortium. These new partners bring unique expertise that will significantly contribute to our mission of accelerating the diagnosis of rare diseases.
UCB Biopharma (UCB)
About UCB
UCB, a leading global biopharmaceutical company, is passionately dedicated to discovering and developing innovative medicines for severe immune and central nervous system diseases. With around 9,000 employees across approximately 40 countries, the company generated €5.3 billion in revenue in 2023 and is listed on Euronext Brussels. UCB's primary focus is on transforming the lives of individuals with neurological and autoimmune conditions. By creating valuable solutions and fostering strong connections with patients, caregivers, healthcare professionals, and stakeholders, UCB is making a profound impact in the healthcare field.
Role within the Screen4Care project
UCB’s comprehensive approach involves active community engagement, integrating their perspectives into all activities. This multifaceted approach, intensified by real patient experiences and partnerships, equips UCB with insights to address the diverse needs of rare disease patients. This knowledge, expertise, and inclusive approach will be applied to their initiative, S4C, to meet the complex needs of rare disease patients and their caregivers.
Wallac OY (Revvity)
About Revvity
As a provider of health science solutions, technologies, expertise, and services, Revvity offers comprehensive workflows spanning from discovery to development and diagnosis to cure. The company is reshaping the boundaries of healthcare by focusing on specialised areas such as translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. With revenue exceeding $2.7 billion in 2023 and a workforce of over 11,000 employees, Revvity caters to a wide range of customers across pharmaceutical and biotech sectors, diagnostic labs, academia, and governments, operating globally with a presence in over 190 countries and being listed on the S&P 500 index.
Role within the Screen4Care Project
Leveraging over 30 years of expertise in newborn screening, Revvity's primary focus within the Screen4Care project is concentrating on innovative rare diseases (RDs) gene panels and whole-genome sequencing (WGS) approaches for genetic newborn screening (NBS).
CHU Dijon Bourgogne
About CHU Dijon Bourgogne
The CHU Dijon-Bourgogne serves as the most significant public healthcare institution in the Bourgogne Franche-Comté region of France, functioning as both a primary healthcare centre and a regional referral facility. Upholding a triple mission of care, education, and research, CHU Dijon-Bourgogne's unwavering commitment to patient care is evident. Striving for continuous innovation to deliver optimal patient care, the CHU Dijon-Bourgogne is deeply engaged in clinical research, serving as a sponsor and investigator centre across various medical and paramedical domains. Known for its rare disease care expertise, CHU Dijon hosts ten accredited Rare Diseases Reference Centers and 53 Rare Diseases Competence Centers. The Genetics Centre within CHU Dijon-Bourgogne, with its top-ranking status in France's Medical Genetics Services and two researchers in the prestigious Stanford classification, is a testament to its dedication to facilitating access to diagnostic innovations and offering specialised consultations for individuals with hereditary diseases. It provides genomic medicine consultations to expedite diagnostic processes and alleviate the diagnostic odyssey for patients.
Role within the Screen4Care Project
CHU Dijon-Bourgogne serves as a principal investigator for France in the Screen4Care project, focusing on extended newborn screening (NBS) using the TREAT panel and aiming to include 1000 newborns in the study. The centre's project team is also actively engaged in the whole-genome sequencing (WGS) approach for genetic NBS. They also contribute to the Project Management and Dissemination group and participate in working groups related to its tasks. Their collaboration with Eurordis on various initiatives, such as defining the concept of actionability, developing the ACT-Panel, and contributing to the NBS forum, further enhances their role in the project.
